Cargando…

Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease

Hyperkalaemia continues to be a major hazard of mineralocorticoid receptor blockade in an effort to retard the progression of chronic kidney disease (CKD). In cardiac patients on mineralocorticoid receptor blockade, RLY-5016 which captures K(+) in the colon has been effective in reducing the risk of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ritz, E., Pitt, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438399/ https://www.ncbi.nlm.nih.gov/pubmed/26120440 http://dx.doi.org/10.1093/ckj/sft084

Ejemplares similares

Mineralocorticoid receptor blockade—a novel approach to fight hyperkalaemia in chronic kidney disease
por: Ritz, Eberhard, et al.
Publicado: (2013)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
por: Henrysson, Josefin, et al.
Publicado: (2022)

Severe hyperkalaemia: demographics and outcome
por: Phillips, B.M., et al.
Publicado: (2014)

Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists
por: Trevisan, Marco, et al.
Publicado: (2018)

Mineralocorticoid receptor blockade for renoprotection
por: Cha, Dae Ryong
Publicado: (2018)

Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2021)

Dietary Approach to Recurrent or Chronic Hyperkalaemia in Patients with Decreased Kidney Function
por: Cupisti, Adamasco, et al.
Publicado: (2018)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in High‐Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease
por: Pitt, Bertram, et al.
Publicado: (2017)

Patterns of chronic and transient hyperkalaemia and clinically important outcomes in patients with chronic kidney disease
por: Trevisan, Marco, et al.
Publicado: (2021)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain
por: Olry de Labry Lima, Antonio, et al.
Publicado: (2021)

Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension
por: Mansur, Arian, et al.
Publicado: (2023)

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease
por: Pitt, Bertram, et al.
Publicado: (2018)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

Effects of Chronic Kidney Disease on Nanomechanics of the Endothelial Glycocalyx Are Mediated by the Mineralocorticoid Receptor
por: Fels, Benedikt, et al.
Publicado: (2022)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

Effect of Mineralocorticoid Receptor Blockade on Hippocampal-Dependent Memory in Obese Adults
por: Rotenstein, Lisa S., et al.
Publicado: (2015)

Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study
por: Kario, Kazuomi, et al.
Publicado: (2020)

Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?
por: Pitt, Bertram, et al.
Publicado: (2015)

Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease
por: Folkerts, Kerstin, et al.
Publicado: (2022)

Management of hyperkalaemia in adults.
por: McVeigh, G.
Publicado: (2005)

Hyperkalaemia in Heart Failure
por: Ismail, Umar, et al.
Publicado: (2021)

The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland
por: Ward, Thomas, et al.
Publicado: (2022)

Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus
por: Wish, Jay B., et al.
Publicado: (2022)

Endovascular renal denervation: a novel sympatholytic with relevance to chronic kidney disease
por: Hoye, Neil A., et al.
Publicado: (2014)

Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges
por: Fujii, Wataru, et al.
Publicado: (2023)

Prevalence and factors associated with hyperkalaemia in stable kidney transplant recipients
por: Smyrli, Maria, et al.
Publicado: (2021)

Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere!
por: Rossignol, Patrick, et al.
Publicado: (2023)

Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease
por: Cooper, Lauren B., et al.
Publicado: (2017)

Bariatric surgery and the kidney—much benefit, but also potential harm
por: Ritz, Eberhard
Publicado: (2013)

Mineralocorticoid Receptor Blockade Improves Coronary Microvascular Function in Individuals With Type 2 Diabetes
por: Garg, Rajesh, et al.
Publicado: (2015)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
por: Pieronne‐Deperrois, Marie, et al.
Publicado: (2021)

Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
por: Wu, Yichuan, et al.
Publicado: (2022)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

New frontiers for management of hyperkalaemia: the emergence of novel agents
por: Nassif, Michael E, et al.
Publicado: (2019)

Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease
por: Spencer, Sarah, et al.
Publicado: (2020)

Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease
por: Oka, Tatsufumi, et al.
Publicado: (2022)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b1e1i6b7ngme9166mof5ke063c